Maxcyte Inc (MXCT)

Apr 04, 2025

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Apr 04, 2025

Apr 03, 2025

MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia

Apr 03, 2025

Apr 03, 2025

MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 01, 2025

MaxCyte Expands Capital with New Stock Issuance - TipRanks

Apr 01, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Decreases Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Mar 30, 2025

Mar 27, 2025

MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com

Mar 27, 2025

Mar 26, 2025

MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India

Mar 26, 2025

Mar 26, 2025

MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks

Mar 26, 2025

Mar 25, 2025

MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks

Mar 25, 2025

Mar 24, 2025

Bank of New York Mellon Corp Reduces Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Mar 24, 2025

Mar 24, 2025

MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

MaxCyte executives receive equity incentives - Investing.com India

Mar 24, 2025

Mar 24, 2025

MaxCyte Awards Stock Options and Units to Executives - TipRanks

Mar 24, 2025

Mar 21, 2025

Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 20, 2025

MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India

Mar 20, 2025

Mar 20, 2025

Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com

Mar 20, 2025

Mar 20, 2025

Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com

Mar 20, 2025

Mar 19, 2025

BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks

Mar 19, 2025

Mar 15, 2025

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha

Mar 15, 2025

Mar 15, 2025

What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World

Mar 15, 2025

Mar 14, 2025

US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World

Mar 14, 2025

Mar 14, 2025

Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World

Mar 14, 2025

Mar 13, 2025

MaxCyte files annual report with SEC By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 12, 2025

MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com

Mar 12, 2025

Mar 12, 2025

MaxCyte stock touches 52-week low at $3.11 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks

Mar 12, 2025

Mar 12, 2025

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 12, 2025

Mar 12, 2025

MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks

Mar 12, 2025

Mar 12, 2025

MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 12, 2025

MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks

Mar 12, 2025

Mar 12, 2025

MaxCyte stock price target cut to $6 at BTIG - Investing.com India

Mar 12, 2025

Mar 12, 2025

MaxCyte files annual report with SEC - Investing.com India

Mar 12, 2025

Mar 12, 2025

MaxCyte core business revenue grows despite overall decline - Investing.com India

Mar 12, 2025

Mar 12, 2025

Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews

Mar 12, 2025